140 related articles for article (PubMed ID: 32482651)
21. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
[TBL] [Abstract][Full Text] [Related]
22. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
[TBL] [Abstract][Full Text] [Related]
23. Drug induced stuttering: pharmacovigilance data.
Trenque T; Morel A; Trenque A; Azzouz B
Expert Opin Drug Saf; 2021 Mar; 20(3):373-378. PubMed ID: 33337944
[No Abstract] [Full Text] [Related]
24. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.
Fernandez S; Lenoir C; Samer C; Rollason V
Pharmacol Res Perspect; 2020 Oct; 8(5):e00647. PubMed ID: 32881416
[TBL] [Abstract][Full Text] [Related]
25. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
26. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
[TBL] [Abstract][Full Text] [Related]
28. Paradoxical adverse drug reactions: descriptive analysis of French reports.
Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
[TBL] [Abstract][Full Text] [Related]
29. The impact of pharmacovigilance on drug portfolio management.
Bucurescu S
Eur Rev Med Pharmacol Sci; 2014; 18(15):2237-9. PubMed ID: 25070831
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
Cliff-Eribo KO; Sammons H; Choonara I
Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
[TBL] [Abstract][Full Text] [Related]
31. Signal selection and follow-up in pharmacovigilance.
Meyboom RH; Lindquist M; Egberts AC; Edwards IR
Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
[TBL] [Abstract][Full Text] [Related]
32. The Work of the Council for International Organizations of Medical Sciences (CIOMS) in Global Pharmacovigilance.
Younus MM; Zweygarth M; Rägo L; Harrison-Woolrych M
Drug Saf; 2020 Nov; 43(11):1067-1071. PubMed ID: 33034859
[No Abstract] [Full Text] [Related]
33. The value of case reports in pharmacovigilance.
Garcia-Doval I; Segovia E; Hunter H; Frew J; Naldi L
Br J Dermatol; 2020 Nov; 183(5):795-796. PubMed ID: 33135791
[No Abstract] [Full Text] [Related]
34. The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database.
Pierson-Marchandise M; Gras V; Moragny J; Micallef J; Gaboriau L; Picard S; Choukroun G; Masmoudi K; Liabeuf S;
Br J Clin Pharmacol; 2017 Jun; 83(6):1341-1349. PubMed ID: 28002877
[TBL] [Abstract][Full Text] [Related]
35. Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database.
Duron D; Blaise S; Cracowski JL; Roustit M; Khouri C
J Am Acad Dermatol; 2021 Jul; 85(1):229-232. PubMed ID: 32781179
[No Abstract] [Full Text] [Related]
36. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center].
Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T
Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165
[TBL] [Abstract][Full Text] [Related]
37. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
[TBL] [Abstract][Full Text] [Related]
38. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
39. Causality assessment in pharmacovigilance: The French method and its successive updates.
Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
[TBL] [Abstract][Full Text] [Related]
40. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature.
Sartori D; Aronson JK; Onakpoya IJ
Syst Rev; 2020 Aug; 9(1):180. PubMed ID: 32791982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
